2024 Conference Coverage
Multi-Institutional Study of Neurologic Outcomes in People With Multiple Sclerosis Who Are Treated With Immune Checkpoint Inhibitors (ICIs) for Oncologic Indications
Login to view comments.
Click here to Login
Videos